Last updated: July 17, 2026

Application No. 18/289,049

ASSESSING AND TREATING CANCER

Non-Final OA

Filed

Oct 31, 2023

Priority

May 06, 2021 — provisional 63/185,325 +2 more

Examiner

METCALF, MATTHEW CURRAN

Art Unit

1647

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

Mayo Foundation for Medical Education and Research

OA Round

1 (Non-Final)

Interview Optional

— +0.0% interview lift. Interview lift (+0.0%) is below the 15.0% threshold. A written response is recommended.

Based on 2 resolved cases, 2023–2026

Examiner Intelligence

METCALF, MATTHEW CURRAN View full profile →

Grants 50% of resolved cases

Career Allowance Rate

1 granted / 2 resolved

-10.0% vs TC avg

Minimal +0% lift

Without

With

+0.0%

Interview Lift

resolved cases with interview

Typical timeline

4y 4m

Avg Prosecution

18 currently pending

Career history

Total Applications

across all art units

Statute-Specific Performance

§103

53.3%

+13.3% vs TC avg

§102

2.2%

-37.8% vs TC avg

§112

2.2%

-37.8% vs TC avg

Black line = Tech Center average estimate • Based on career data from 2 resolved cases

Prosecution Timeline

Oct 31, 2023

Application Filed

May 06, 2026

Non-Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

18/194,360

Patent 12637518

DUAL SPECIFICITY ANTIBODIES TO HUMAN PD-L1 AND PD-L2 AND METHODS OF USE THEREFOR

3y 1m to grant Granted May 26, 2026

Study what changed to get past this examiner. Based on 1 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2

Expected OA Rounds

50%

Grant Probability

50%

With Interview (+0.0%)

4y 4m (~1y 8m remaining)

Median Time to Grant

Low

PTA Risk

Based on 2 resolved cases by this examiner. Grant probability derived from career allowance rate.